This implies that a combination of chemotherapy with novel agents eliciting LKB1-AMPK pathway inhibition would be efficacious as an upfront approach to treat ovarian cancer patients with late-stage disease to better eradicate residual dormant micro-metastases and reduce chemo-resistant disease recurrence. The gene discussed is STK11; the disease is ovarian carcinoma.